The expanding success of T cell-engaging bispecific antibodies
Crossref DOI link: https://doi.org/10.1038/s43018-023-00586-z
Published Online: 2023-06-14
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bargou, Ralf C.
Text and Data Mining valid from 2023-06-14
Version of Record valid from 2023-06-14
Article History
First Online: 14 June 2023
Competing interests
: R.C.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex and Gemoab.